Bayer's Stroke Drug Is Shipping on Schedule, but the Numbers That Matter Are Still Being Written Elsewhere
Published on 11/22/2026 at 05:52 | Editorial boerse-global.deHospitals, health systems and pharmacies across the United States have been able to order Sunharbo since November 20. Bayer's new anticoagulant, whose active ingredient is asundexian, comes as a 50-milligram tablet and is cleared for adults who have recently suffered a non-cardioembolic ischemic stroke or a high-risk TIA. Patients take it on top of an antiplatelet agent to lower the odds of a second stroke.
The launch hit its own timetable. In its November 9 approval announcement, Bayer had pointed to shipping in mid-to-late November, with ordering to open shortly after. The drug became orderable eleven days later — comfortably inside that window, if at the early end of it. For a product entering a new therapeutic field, getting approval, manufacturing and distribution to line up is no small feat, and on that measure the group delivered what it promised.
One Price Tag, and a Lot of Silence
Only a single commercial figure emerges from the launch notice: a list price of just under USD 750 for 30 days of treatment. Bayer is quick to qualify it — that is not what most insurers or patients will ultimately pay.
What the announcement does not contain is any order volume, any sales figure or any revenue booked so far. Being orderable means large buyers can stock their shelves; nothing more. The calendar adds its own constraint: in the current fiscal year, Sunharbo will be on sale for just 42 calendar days, launch day included.
Should investors sell immediately? Or is it worth buying Bayer?
The Numbers Actually Moving Bayer
Set that against a company that booked just over EUR 10 billion in the third quarter, up from close to EUR 9.7 billion a year earlier — and still posted a loss of EUR 672 million, narrower than the EUR 963 million shortfall of the prior-year period. Bayer's results are currently being shaped by items of an entirely different magnitude.
One of them landed on the very day Sunharbo became orderable. On November 20, a court in Missouri granted final approval to the nationwide Roundup settlement, which provides for payments of no more than USD 7.25 billion in total, spread over as many as 21 years and inclusive of sums already disbursed. Judge Timothy Boyer signed off on the deal; according to Deutschlandfunk, it is not yet legally final. Chief executive Bill Anderson called the approval a decisive milestone in containing pending and potential future litigation.
When the Money Actually Leaves
For investors, the timing of the cash outflow matters as much as the headline figure. Monsanto is to pay into a compensation fund over up to 21 years, with annual amounts capped and set to decline. An appeal could suspend the payments until the appellate process concludes — which is why the annual ceilings, not just the total, govern how much cash leaves the company in any given year. Payments already made count toward the fund's contributions.
The settlement is designed to capture the bulk of current and potential future US claims tied to non-Hodgkin lymphoma. It also covers compensation for people diagnosed within 16 years of the agreement taking effect, provided they had contact with Roundup before February 17. How many claimants will join has not been published, so the reach of the deal depends in part on how many affected parties route their claims through the fund.
Reuters puts the number of pending claims at roughly 65,000. About 200 cases before federal courts fall outside the settlement. The agreement carries no admission of liability; Bayer continues to deny that Roundup causes cancer.
Bayer at a turning point? This analysis reveals what investors need to know now.
A Long Ledger, and a Margin Raised Without Sunharbo
Since acquiring Monsanto in 2018, Bayer has already paid out around USD 10 billion in settlements, according to Deutschlandfunk. In June, the US Supreme Court also ruled that certain claims over the absence of cancer warnings on Roundup packaging are precluded.
Meanwhile, the improved mood in the pharmaceuticals division has nothing to do with the new stroke drug. Bayer has lifted its expected 2026 margin for the division, before special items, to 25 to 27 percent from 23 to 25 percent — and attributes the upgrade explicitly to business performance in the first nine months of the year. At that point, Sunharbo was not even approved in the US. The raised guidance rests on the existing portfolio, not on the newcomer.
Bayer has shown that approval, production and distribution can interlock as planned, and that is a genuine operational step. A measurable contribution to the group's financials, however, has yet to be demonstrated.
Ad
Bayer Stock: New Analysis - 22 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
